Financing to be conducted by Cowen, Stifel, Baird and H.C. Wainwright
By Devika Patel
Knoxville, Tenn., June 17 – Nivalis Therapeutics, Inc. said it priced its $77 million initial public offering of stock with an $11.55 million greenshoe. The deal was announced May 13.
The company will sell 5.5 million common shares at $14.00 per share.
Cowen and Co. LLC and Stifel, Nicolaus & Co., Inc. are the bookrunners.
Settlement is expected June 22.
Proceeds will be used for clinical programs and development activities and for working capital and other general corporate purposes, including operations.
| Issuer: | Nivalis Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $77 million
|
| Greenshoe: | $11.55 million, or 825,000 shares
|
| Shares: | 5.5 million
|
| Price: | $14.00
|
| Warrants: | No
|
| Bookrunners: | Cowen and Co. LLC and Stifel, Nicolaus & Co., Inc.
|
| Co-managers: | Robert W. Baird & Co. Inc. and H.C. Wainwright & Co., LLC
|
| Announcement date: | May 13
|
| Pricing date: | June 17
|
| Settlement date: | June 22
|
| Stock symbol: | Nasdaq: NVLS
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
